Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents

Woong Chol Kang, T. H. Ahn, C. I. Moon, S. H. Han, E. K. Shin, J. S. Kim, Y. G. Ko, Donghoon Choi, Yangsoo Jang, B. K. Kim, S. J. Oh, D. W. Jeon, J. Y. Yang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: We compared the degree of systemic inflammation and its relation to the angiographic outcomes after drug-eluting stent (DES) implantations. Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4 (9.5) years of age; sirolimuseluting stent (SES), n=38; paclitaxel-eluting stent (PES), n=41). The high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) levels were determined before and at 24 hours, 72 hours, and 4 weeks after the percutaneous coronary intervention (PCI). An angiography and intravascular ultrasound (IVUS) were performed. Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hours and 72 hours after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hours after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow-up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57 (0.56) mm vs 0.28 (0.58) mm, respectively, p = 0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1 (22.7) vs 3.8 (7.1) mm3, respectively, p = 0.000). The percentage luminal volume reduction was higher in the PES group than in the SES group (18.9 vs 3.9%, p = 0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction. Conclusions: Our study showed that the benefits obtained from the SES, which reduce neointimal proliferation, are not probably mediated by the attenuation of the systemic inflammatory markers hs-CRP or IL-6.

Original languageEnglish
Pages (from-to)970-975
Number of pages6
JournalHeart
Volume95
Issue number12
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

Sirolimus
Paclitaxel
Stents
C-Reactive Protein
Interleukin-6
Percutaneous Coronary Intervention
Drug-Eluting Stents
Hyperplasia
Stable Angina
Angiography
Inflammation

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kang, W. C., Ahn, T. H., Moon, C. I., Han, S. H., Shin, E. K., Kim, J. S., ... Yang, J. Y. (2009). Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart, 95(12), 970-975. https://doi.org/10.1136/hrt.2008.153114
Kang, Woong Chol ; Ahn, T. H. ; Moon, C. I. ; Han, S. H. ; Shin, E. K. ; Kim, J. S. ; Ko, Y. G. ; Choi, Donghoon ; Jang, Yangsoo ; Kim, B. K. ; Oh, S. J. ; Jeon, D. W. ; Yang, J. Y. / Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. In: Heart. 2009 ; Vol. 95, No. 12. pp. 970-975.
@article{cdc8fc37915542528b60932b5d03ef24,
title = "Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents",
abstract = "Objective: We compared the degree of systemic inflammation and its relation to the angiographic outcomes after drug-eluting stent (DES) implantations. Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4 (9.5) years of age; sirolimuseluting stent (SES), n=38; paclitaxel-eluting stent (PES), n=41). The high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) levels were determined before and at 24 hours, 72 hours, and 4 weeks after the percutaneous coronary intervention (PCI). An angiography and intravascular ultrasound (IVUS) were performed. Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hours and 72 hours after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hours after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow-up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57 (0.56) mm vs 0.28 (0.58) mm, respectively, p = 0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1 (22.7) vs 3.8 (7.1) mm3, respectively, p = 0.000). The percentage luminal volume reduction was higher in the PES group than in the SES group (18.9 vs 3.9{\%}, p = 0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction. Conclusions: Our study showed that the benefits obtained from the SES, which reduce neointimal proliferation, are not probably mediated by the attenuation of the systemic inflammatory markers hs-CRP or IL-6.",
author = "Kang, {Woong Chol} and Ahn, {T. H.} and Moon, {C. I.} and Han, {S. H.} and Shin, {E. K.} and Kim, {J. S.} and Ko, {Y. G.} and Donghoon Choi and Yangsoo Jang and Kim, {B. K.} and Oh, {S. J.} and Jeon, {D. W.} and Yang, {J. Y.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1136/hrt.2008.153114",
language = "English",
volume = "95",
pages = "970--975",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "12",

}

Kang, WC, Ahn, TH, Moon, CI, Han, SH, Shin, EK, Kim, JS, Ko, YG, Choi, D, Jang, Y, Kim, BK, Oh, SJ, Jeon, DW & Yang, JY 2009, 'Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents', Heart, vol. 95, no. 12, pp. 970-975. https://doi.org/10.1136/hrt.2008.153114

Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. / Kang, Woong Chol; Ahn, T. H.; Moon, C. I.; Han, S. H.; Shin, E. K.; Kim, J. S.; Ko, Y. G.; Choi, Donghoon; Jang, Yangsoo; Kim, B. K.; Oh, S. J.; Jeon, D. W.; Yang, J. Y.

In: Heart, Vol. 95, No. 12, 01.06.2009, p. 970-975.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents

AU - Kang, Woong Chol

AU - Ahn, T. H.

AU - Moon, C. I.

AU - Han, S. H.

AU - Shin, E. K.

AU - Kim, J. S.

AU - Ko, Y. G.

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Kim, B. K.

AU - Oh, S. J.

AU - Jeon, D. W.

AU - Yang, J. Y.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Objective: We compared the degree of systemic inflammation and its relation to the angiographic outcomes after drug-eluting stent (DES) implantations. Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4 (9.5) years of age; sirolimuseluting stent (SES), n=38; paclitaxel-eluting stent (PES), n=41). The high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) levels were determined before and at 24 hours, 72 hours, and 4 weeks after the percutaneous coronary intervention (PCI). An angiography and intravascular ultrasound (IVUS) were performed. Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hours and 72 hours after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hours after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow-up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57 (0.56) mm vs 0.28 (0.58) mm, respectively, p = 0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1 (22.7) vs 3.8 (7.1) mm3, respectively, p = 0.000). The percentage luminal volume reduction was higher in the PES group than in the SES group (18.9 vs 3.9%, p = 0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction. Conclusions: Our study showed that the benefits obtained from the SES, which reduce neointimal proliferation, are not probably mediated by the attenuation of the systemic inflammatory markers hs-CRP or IL-6.

AB - Objective: We compared the degree of systemic inflammation and its relation to the angiographic outcomes after drug-eluting stent (DES) implantations. Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4 (9.5) years of age; sirolimuseluting stent (SES), n=38; paclitaxel-eluting stent (PES), n=41). The high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) levels were determined before and at 24 hours, 72 hours, and 4 weeks after the percutaneous coronary intervention (PCI). An angiography and intravascular ultrasound (IVUS) were performed. Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hours and 72 hours after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hours after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow-up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57 (0.56) mm vs 0.28 (0.58) mm, respectively, p = 0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1 (22.7) vs 3.8 (7.1) mm3, respectively, p = 0.000). The percentage luminal volume reduction was higher in the PES group than in the SES group (18.9 vs 3.9%, p = 0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction. Conclusions: Our study showed that the benefits obtained from the SES, which reduce neointimal proliferation, are not probably mediated by the attenuation of the systemic inflammatory markers hs-CRP or IL-6.

UR - http://www.scopus.com/inward/record.url?scp=67649219023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649219023&partnerID=8YFLogxK

U2 - 10.1136/hrt.2008.153114

DO - 10.1136/hrt.2008.153114

M3 - Article

C2 - 18772180

AN - SCOPUS:67649219023

VL - 95

SP - 970

EP - 975

JO - Heart

JF - Heart

SN - 1355-6037

IS - 12

ER -